The Lao Big Bear version of Avatrombopag is a compliantly manufactured generic drug, providing patients with thrombocytopenia a treatment option that is as effective as the original drug but more affordable.
What are the purchasing channels for the Lao Big Bear version of Avatrombopag?
The Lao Big Bear version of Avatrombopag is available in a specification of 20mg*30 tablets/box. For specific purchasing methods, we recommend adding professional customer service for detailed consultation.
Recommended dosage and usage instructions for Avatrombopag
The recommended dosage of Avatrombopag depends on the patient's platelet count before the scheduled surgery. For patients with a baseline platelet count below 40,000/uL, the recommended dose is 60 mg orally once daily for 5 consecutive days. For patients with a baseline platelet count between 40,000 and below 50,000/uL, the recommended dose is 40 mg orally once daily, also for 5 consecutive days. Patients should strictly follow the doctor's instructions and start taking the medication 5 days before the scheduled surgery. If a dose is missed, it should be taken as soon as possible, but never take a double dose; take the next dose at the normal time the next day and complete the full 5-day course. In case of accidental overdose, contact a doctor immediately or go to the nearest emergency room. After the treatment course, surgery should be scheduled 5 to 8 days after the last dose.
Avatrombopag significantly reduces the need for preoperative platelet transfusions
The primary efficacy endpoint in two clinical trials was the proportion of patients who did not require platelet transfusion or any rescue procedure for bleeding from randomization to within 7 days after elective surgery. Results showed that in the low baseline platelet cohort , in the ADAPT-1 trial, 66% of patients in the Avatrombopag group achieved the efficacy endpoint compared to only 23% in the placebo group, a treatment difference of 43%; in the ADAPT-2 trial, the Avatrombopag group had a response rate of 69% versus 35% in the placebo group, a treatment difference of 34%. In the high baseline platelet cohort, the Avatrombopag groups in both trials had a response rate of 88%, while the placebo groups had rates of 38% and 33%, respectively, with treatment differences of 50% and 55%. All comparisons were highly statistically significant, fully confirming the superiority of Avatrombopag in preventing surgery-related bleeding events.
